BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Proschak E, Stark H, Merk D. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. J Med Chem 2019;62:420-44. [PMID: 30035545 DOI: 10.1021/acs.jmedchem.8b00760] [Cited by in Crossref: 144] [Cited by in F6Publishing: 119] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, Li W, Ouyang L, Wang Y. Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. J Med Chem 2021;64:7963-90. [PMID: 34101463 DOI: 10.1021/acs.jmedchem.1c00100] [Reference Citation Analysis]
2 Bajorath J. Structural characteristics of compounds with multitarget activity. Future Drug Discovery 2021;3:FDD60. [DOI: 10.4155/fdd-2021-0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Chaudhari R, Fong LW, Tan Z, Huang B, Zhang S. An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opin Drug Discov 2020;15:1025-44. [PMID: 32452701 DOI: 10.1080/17460441.2020.1767063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mohammed HHH, Abd El-Hafeez AA, Ebeid K, Mekkawy AI, Abourehab MAS, Wafa EI, Alhaj-Suliman SO, Salem AK, Ghosh P, Abuo-Rahma GEA, Hayallah AM, Abbas SH. New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. J Enzyme Inhib Med Chem 2022;37:1346-63. [PMID: 35548854 DOI: 10.1080/14756366.2022.2072308] [Reference Citation Analysis]
5 Lemke C, Christmann J, Yin J, Alonso JM, Serrano E, Chioua M, Ismaili L, Martínez-Grau MA, Beadle CD, Vetman T, Dato FM, Bartz U, Elsinghorst PW, Pietsch M, Müller CE, Iriepa I, Wille T, Marco-Contelles J, Gütschow M. Chromenones as Multineurotargeting Inhibitors of Human Enzymes. ACS Omega 2019;4:22161-8. [PMID: 31891098 DOI: 10.1021/acsomega.9b03409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mehta P, Miszta P, Filipek S. Molecular Modeling of Histamine Receptors-Recent Advances in Drug Discovery. Molecules 2021;26:1778. [PMID: 33810008 DOI: 10.3390/molecules26061778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Jiang X, Zhou J, Wang Y, Chen L, Duan Y, Huang J, Liu C, Chen Y, Liu W, Sun H, Feng F, Qu W. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. European Journal of Medicinal Chemistry 2020;207:112751. [DOI: 10.1016/j.ejmech.2020.112751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bolognesi ML. Harnessing Polypharmacology with Medicinal Chemistry. ACS Med Chem Lett 2019;10:273-5. [PMID: 30891125 DOI: 10.1021/acsmedchemlett.9b00039] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 21.7] [Reference Citation Analysis]
9 Rodríguez-Soacha DA, Scheiner M, Decker M. Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. Eur J Med Chem 2019;180:690-706. [PMID: 31401465 DOI: 10.1016/j.ejmech.2019.07.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
10 Wang Y, Tortorella M. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review. Eur J Med Chem 2022;228:114039. [PMID: 34894440 DOI: 10.1016/j.ejmech.2021.114039] [Reference Citation Analysis]
11 Tomovic K, Ilic BS, Smelcerovic Z, Miljkovic M, Yancheva D, Kojic M, Mavrova AT, Kocic G, Smelcerovic A. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. Chemico-Biological Interactions 2020;315:108873. [DOI: 10.1016/j.cbi.2019.108873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Tan L, Zhang J, Wang Y, Wang X, Wang Y, Zhang Z, Shuai W, Wang G, Chen J, Wang C, Ouyang L, Li W. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. J Med Chem 2022. [PMID: 35311289 DOI: 10.1021/acs.jmedchem.1c01714] [Reference Citation Analysis]
13 Zajdel P, Grychowska K, Mogilski S, Kurczab R, Satała G, Bugno R, Kos T, Gołębiowska J, Malikowska-Racia N, Nikiforuk A, Chaumont-Dubel S, Bantreil X, Pawłowski M, Martinez J, Subra G, Lamaty F, Marin P, Bojarski AJ, Popik P. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties. J Med Chem 2021;64:13279-98. [PMID: 34467765 DOI: 10.1021/acs.jmedchem.1c00224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Scheiner M, Dolles D, Gunesch S, Hoffmann M, Nabissi M, Marinelli O, Naldi M, Bartolini M, Petralla S, Poeta E, Monti B, Falkeis C, Vieth M, Hübner H, Gmeiner P, Maitra R, Maurice T, Decker M. Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. J Med Chem 2019;62:9078-102. [PMID: 31609608 DOI: 10.1021/acs.jmedchem.9b00623] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
15 Hrast M, Rožman K, Ogris I, Škedelj V, Patin D, Sova M, Barreteau H, Gobec S, Grdadolnik SG, Zega A. Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases. J Enzyme Inhib Med Chem 2019;34:1010-7. [PMID: 31072165 DOI: 10.1080/14756366.2019.1608981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
16 Martínez-González S, Alvarez RM, Martín JI, García AB, Riesco-Fagundo C, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Albarrán MI, Gómez-Casero E, Cebriá A, Aguirre E, Ajenjo N, Cebrián D, Di Geronimo B, Cunningham D, O'Neill M, Dave HPG, Blanco-Aparicio C, Pastor J. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Med Chem Lett 2021;12:1794-801. [PMID: 34795869 DOI: 10.1021/acsmedchemlett.1c00412] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mbaba M, Dingle LMK, Swart T, Cash D, Laming D, de la Mare JA, Taylor D, Hoppe HC, Biot C, Edkins AL, Khanye SD. The in Vitro Antiplasmodial and Antiproliferative Activity of New Ferrocene-Based α-Aminocresols Targeting Hemozoin Inhibition and DNA Interaction. Chembiochem 2020;21:2643-58. [PMID: 32307798 DOI: 10.1002/cbic.202000132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yoshimori A, Hu H, Bajorath J. Adapting the DeepSARM approach for dual-target ligand design. J Comput Aided Mol Des 2021;35:587-600. [PMID: 33712972 DOI: 10.1007/s10822-021-00379-5] [Reference Citation Analysis]
19 Pepi MJ, Chacko S, Marqus GM, Singh V, Wang Z, Planck K, Cullinane RT, Meka PN, Gollapalli DR, Ioerger TR, Rhee KY, Cuny GD, Boshoff HIM, Hedstrom L. A d-Phenylalanine-Benzoxazole Derivative Reveals the Role of the Essential Enzyme Rv3603c in the Pantothenate Biosynthetic Pathway of Mycobacterium tuberculosis. ACS Infect Dis 2022;8:330-42. [PMID: 35015509 DOI: 10.1021/acsinfecdis.1c00461] [Reference Citation Analysis]
20 Blaschke T, Bajorath J. Compound dataset and custom code for deep generative multi-target compound design. Future Sci OA 2021;7:FSO715. [PMID: 34046209 DOI: 10.2144/fsoa-2021-0033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kartsev V, Shikhaliev KS, Geronikaki A, Medvedeva SM, Ledenyova IV, Krysin MY, Petrou A, Ciric A, Glamoclija J, Sokovic M. Appendix A. dithioloquinolinethiones as new potential multitargeted antibacterial and antifungal agents: Synthesis, biological evaluation and molecular docking studies. Eur J Med Chem 2019;175:201-14. [PMID: 31078867 DOI: 10.1016/j.ejmech.2019.04.046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
22 Balali E, Sandi S, Sheikhi M, Shahab S, Kaviani S. DFT and TD-DFT study of adsorption behavior of Zejula drug on surface of the B12N12 nanocluster. MGC 2022. [DOI: 10.3233/mgc-210120] [Reference Citation Analysis]
23 Wilt S, Kodani S, Valencia L, Hudson PK, Sanchez S, Quintana T, Morisseau C, Hammock BD, Kandasamy R, Pecic S. Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors. Bioorg Med Chem 2021;51:116507. [PMID: 34794001 DOI: 10.1016/j.bmc.2021.116507] [Reference Citation Analysis]
24 Koroleva EV, Kornoushenko YV, Karpenko AD, Bosko IP, Siniutsich JV, Ignatovich ZV, Andrianov AM. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2062784] [Reference Citation Analysis]
25 Uliassi E, de Oliveira AS, de Camargo Nascente L, Romeiro LAS, Bolognesi ML. Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer's Disease. Molecules 2021;26:5441. [PMID: 34576912 DOI: 10.3390/molecules26185441] [Reference Citation Analysis]
26 Ruzic D, Djoković N, Srdić-rajić T, Echeverria C, Nikolic K, Santibanez JF. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 2022;14:209. [DOI: 10.3390/pharmaceutics14010209] [Reference Citation Analysis]
27 Signorello MG, Rapetti F, Meta E, Sidibè A, Bruno O, Brullo C. New Series of Pyrazoles and Imidazo-Pyrazoles Targeting Different Cancer and Inflammation Pathways. Molecules 2021;26:5735. [PMID: 34641279 DOI: 10.3390/molecules26195735] [Reference Citation Analysis]
28 Pinzi L. On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Res 2022;11:237. [DOI: 10.12688/f1000research.108761.2] [Reference Citation Analysis]
29 Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. [DOI: 10.1038/s41573-022-00472-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Valdés-jiménez A, Jiménez-gonzález D, Kiper AK, Rinné S, Decher N, González W, Reyes-parada M, Núñez-vivanco G. A New Strategy for Multitarget Drug Discovery/Repositioning Through the Identification of Similar 3D Amino Acid Patterns Among Proteins Structures: The Case of Tafluprost and its Effects on Cardiac Ion Channels. Front Pharmacol 2022;13:855792. [DOI: 10.3389/fphar.2022.855792] [Reference Citation Analysis]
31 Garces AE, Stocks MJ. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. J Med Chem 2019;62:4815-50. [DOI: 10.1021/acs.jmedchem.8b01492] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
32 Feldmann C, Yonchev D, Bajorath J. Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. Biomolecules 2020;10:E1605. [PMID: 33260876 DOI: 10.3390/biom10121605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cianni L, Feldmann CW, Gilberg E, Gütschow M, Juliano L, Leitão A, Bajorath J, Montanari CA. Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity? J Med Chem 2019;62:10497-525. [DOI: 10.1021/acs.jmedchem.9b00683] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
34 Jörg M, Madden KS. The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. RSC Med Chem 2021;12:646-65. [PMID: 34124668 DOI: 10.1039/d1md00022e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Jeong GH, Park S, Kim SB, Jo C, Kim TH. Molecular hybridization based on (-)-epigallocatechin gallate as a new class of antiglycation agents. Biosci Biotechnol Biochem 2021;85:1069-76. [PMID: 33704410 DOI: 10.1093/bbb/zbab020] [Reference Citation Analysis]
36 Long MJ, Liu X, Aye Y. Genie in a bottle: controlled release helps tame natural polypharmacology? Curr Opin Chem Biol 2019;51:48-56. [PMID: 30913473 DOI: 10.1016/j.cbpa.2019.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Czopek A, Partyka A, Bucki A, Pawłowski M, Kołaczkowski M, Siwek A, Głuch-Lutwin M, Koczurkiewicz P, Pękala E, Jaromin A, Tyliszczak B, Wesołowska A, Zagórska A. Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives. Molecules 2020;25:E3868. [PMID: 32854402 DOI: 10.3390/molecules25173868] [Reference Citation Analysis]
38 Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, Qu W, Sun H. Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. J Med Chem 2019;62:8881-914. [PMID: 31082225 DOI: 10.1021/acs.jmedchem.9b00017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 21.3] [Reference Citation Analysis]
39 Łażewska D, Bajda M, Kaleta M, Zaręba P, Doroz-Płonka A, Siwek A, Alachkar A, Mogilski S, Saad A, Kuder K, Olejarz-Maciej A, Godyń J, Stary D, Sudoł S, Więcek M, Latacz G, Walczak M, Handzlik J, Sadek B, Malawska B, Kieć-Kononowicz K. Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer's disease. Eur J Med Chem 2020;207:112743. [PMID: 32882609 DOI: 10.1016/j.ejmech.2020.112743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Grotsch K, Fokin VV. Between Science and Big Business: Tapping Mary Jane's Uncharted Potential. ACS Cent Sci 2022;8:156-68. [PMID: 35233448 DOI: 10.1021/acscentsci.1c01100] [Reference Citation Analysis]
41 Adamovich SN, Kondrashov EV, Ushakov IA, Shatokhina NS, Oborina EN, Vashchenko AV, Belovezhets LA, Rozentsveig IB, Verpoort F. Isoxazole derivatives of silatrane: synthesis, characterization, in silico ADME profile, prediction of potential pharmacological activity and evaluation of antimicrobial action. Appl Organomet Chem 2020;34. [DOI: 10.1002/aoc.5976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
42 Zhang B, Liu Z, Xia S, Liu Q, Gou S. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Eur J Med Chem 2021;216:113300. [PMID: 33640672 DOI: 10.1016/j.ejmech.2021.113300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Johnson AD, Buhagiar JA, Magri DC. 4-Amino-1,8-naphthalimide-ferrocene conjugates as potential multi-targeted anticancer and fluorescent cellular imaging agents. RSC Med Chem 2021;12:2060-4. [PMID: 35028564 DOI: 10.1039/d1md00246e] [Reference Citation Analysis]
44 Salerno L, Vanella L, Sorrenti V, Consoli V, Ciaffaglione V, Fallica AN, Canale V, Zajdel P, Pignatello R, Intagliata S. Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation. J Enzyme Inhib Med Chem 2021;36:1378-86. [PMID: 34167427 DOI: 10.1080/14756366.2021.1928111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Ehrt C, Brinkjost T, Koch O. Binding site characterization - similarity, promiscuity, and druggability. Medchemcomm 2019;10:1145-59. [PMID: 31391887 DOI: 10.1039/c9md00102f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
46 Pinzi L, Foschi F, Christodoulou MS, Passarella D, Rastelli G. Design and Synthesis of Hsp90 Inhibitors with B-Raf and PDHK1 Multi-Target Activity. ChemistryOpen 2021;10:1177-85. [PMID: 34633754 DOI: 10.1002/open.202100131] [Reference Citation Analysis]
47 Moumbock AFA, Li J, Mishra P, Gao M, Günther S. Current computational methods for predicting protein interactions of natural products. Comput Struct Biotechnol J 2019;17:1367-76. [PMID: 31762960 DOI: 10.1016/j.csbj.2019.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
48 Kawahara B, Faull KF, Janzen C, Mascharak PK. Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem 2021;64:8437-46. [PMID: 34097831 DOI: 10.1021/acs.jmedchem.1c00404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Pane K, Mirabelli P, Coppola L, Illiano E, Salvatore M, Franzese M. New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis. Front Chem 2020;8:600. [PMID: 32850635 DOI: 10.3389/fchem.2020.00600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Rao S, Du G, Hafner M, Subramanian K, Sorger PK, Gray NS. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem 2019;294:8664-73. [PMID: 30858179 DOI: 10.1074/jbc.RA118.006805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
51 Ladds MJGW, Popova G, Pastor-Fernández A, Kannan S, van Leeuwen IMM, Håkansson M, Walse B, Tholander F, Bhatia R, Verma CS, Lane DP, Laín S. Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. J Biol Chem 2020;295:17935-49. [PMID: 32900849 DOI: 10.1074/jbc.RA119.012056] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chen T, Sun T, Bian Y, Pei Y, Feng F, Chi H, Li Y, Tang X, Sang S, Du C, Chen Y, Chen Y, Sun H. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem . [DOI: 10.1021/acs.jmedchem.1c01456] [Reference Citation Analysis]
53 Heitel P, Faudone G, Helmstädter M, Schmidt J, Kaiser A, Tjaden A, Schröder M, Müller S, Schierle S, Pollinger J, Merk D. A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice. Commun Chem 2020;3. [DOI: 10.1038/s42004-020-00411-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Antolin AA, Clarke PA, Collins I, Workman P, Al-Lazikani B. Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chem Biol 2021:S2451-9456(21)00221-X. [PMID: 34077750 DOI: 10.1016/j.chembiol.2021.05.004] [Reference Citation Analysis]
55 Mathai N, Kirchmair J. Similarity-Based Methods and Machine Learning Approaches for Target Prediction in Early Drug Discovery: Performance and Scope. Int J Mol Sci 2020;21:E3585. [PMID: 32438666 DOI: 10.3390/ijms21103585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
56 Łażewska D, Olejarz-Maciej A, Reiner D, Kaleta M, Latacz G, Zygmunt M, Doroz-Płonka A, Karcz T, Frank A, Stark H, Kieć-Kononowicz K. Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. Int J Mol Sci 2020;21:E3411. [PMID: 32408504 DOI: 10.3390/ijms21103411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Egyed A, Kelemen ÁA, Vass M, Visegrády A, Thee SA, Wang Z, de Graaf C, Brea J, Loza MI, Leurs R, Keserű GM. Controlling the selectivity of aminergic GPCR ligands from the extracellular vestibule. Bioorg Chem 2021;111:104832. [PMID: 33826962 DOI: 10.1016/j.bioorg.2021.104832] [Reference Citation Analysis]
58 Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R, Cohen D. Next-generation drug repurposing using human genetics and network biology. Curr Opin Pharmacol 2020;51:78-92. [PMID: 31982325 DOI: 10.1016/j.coph.2019.12.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
59 Schierle S, Helmstädter M, Schmidt J, Hartmann M, Horz M, Kaiser A, Weizel L, Heitel P, Proschak A, Hernandez-Olmos V, Proschak E, Merk D. Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast. ChemMedChem 2020;15:50-67. [PMID: 31670489 DOI: 10.1002/cmdc.201900576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
60 Dorababu A. Recent update on antibacterial and antifungal activity of quinoline scaffolds. Arch Pharm (Weinheim) 2021;354:e2000232. [PMID: 33210348 DOI: 10.1002/ardp.202000232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Grigolo TA, Braga CB, Ornelas C, Russowsky D, Ferreira-Silva GA, Ionta M, Pilli RA. Hybrids of 4-hydroxy derivatives of goniothalamin and piplartine bearing a diester or a 1,2,3-triazole linker as antiproliferative agents. Bioorg Chem 2021;116:105292. [PMID: 34509797 DOI: 10.1016/j.bioorg.2021.105292] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zagórska A, Bucki A, Partyka A, Jastrzębska-więsek M, Siwek A, Głuch-lutwin M, Mordyl B, Jaromin A, Walczak M, Wesołowska A, Kołaczkowski M. Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. European Journal of Medicinal Chemistry 2022;233:114218. [DOI: 10.1016/j.ejmech.2022.114218] [Reference Citation Analysis]
63 Sakyi PO, Amewu RK, Devine RNOA, Bienibuor AK, Miller WA 3rd, Kwofie SK. Unravelling the myth surrounding sterol biosynthesis as plausible target for drug design against leishmaniasis. J Parasit Dis 2021;45:1152-71. [PMID: 34790000 DOI: 10.1007/s12639-021-01390-1] [Reference Citation Analysis]
64 Konecny J, Misiachna A, Hrabinova M, Pulkrabkova L, Benkova M, Prchal L, Kucera T, Kobrlova T, Finger V, Kolcheva M, Kortus S, Jun D, Valko M, Horak M, Soukup O, Korabecny J. Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists. Biomolecules 2020;11:E3. [PMID: 33375115 DOI: 10.3390/biom11010003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Nayarisseri A. Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery. Curr Top Med Chem 2020;20:1651-60. [PMID: 32614747 DOI: 10.2174/156802662019200701164759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Liu W, Hou C, Li J, Ma X, Zhang Y, Hu M, Huang Y. Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents. J Enzyme Inhib Med Chem 2020;35:187-98. [PMID: 31752552 DOI: 10.1080/14756366.2019.1693703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Ekström F, Gottinger A, Forsgren N, Catto M, Iacovino LG, Pisani L, Binda C. Dual Reversible Coumarin Inhibitors Mutually Bound to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures. ACS Med Chem Lett 2022;13:499-506. [PMID: 35300078 DOI: 10.1021/acsmedchemlett.2c00001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Schäker-Hübner L, Warstat R, Ahlert H, Mishra P, Kraft FB, Schliehe-Diecks J, Schöler A, Borkhardt A, Breit B, Bhatia S, Hügle M, Günther S, Hansen FK. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. J Med Chem 2021;64:14620-46. [PMID: 34582215 DOI: 10.1021/acs.jmedchem.1c01119] [Reference Citation Analysis]
69 Brunst S, Kramer JS, Kilu W, Heering J, Pollinger J, Hiesinger K, George S, Steinhilber D, Merk D, Proschak E. Systematic Assessment of Fragment Identification for Multitarget Drug Design. ChemMedChem 2021;16:1088-92. [PMID: 33283450 DOI: 10.1002/cmdc.202000858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol 2019;166:212-21. [PMID: 31129048 DOI: 10.1016/j.bcp.2019.05.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
71 Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol 2020;11:554961. [PMID: 33776749 DOI: 10.3389/fphar.2020.554961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Ottanà R, Paoli P, Cappiello M, Nguyen TN, Adornato I, Del Corso A, Genovese M, Nesi I, Moschini R, Naß A, Wolber G, Maccari R. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B. Molecules 2021;26:E330. [PMID: 33435264 DOI: 10.3390/molecules26020330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Fallica AN, Pittalà V, Modica MN, Salerno L, Romeo G, Marrazzo A, Helal MA, Intagliata S. Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. J Med Chem 2021;64:7926-62. [PMID: 34076441 DOI: 10.1021/acs.jmedchem.0c02265] [Reference Citation Analysis]
74 He X, Zhao L, Zhong W, Chen HY, Shan X, Tang N, Chen CY. Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms. Biomed Pharmacother 2020;129:110360. [PMID: 32559623 DOI: 10.1016/j.biopha.2020.110360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Schierle S, Neumann S, Heitel P, Willems S, Kaiser A, Pollinger J, Merk D. Design and Structural Optimization of Dual FXR/PPARδ Activators. J Med Chem 2020;63:8369-79. [PMID: 32687365 DOI: 10.1021/acs.jmedchem.0c00618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Feldmann C, Yonchev D, Bajorath J. Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays. Future Sci OA 2021;7:FSO685. [PMID: 34046190 DOI: 10.2144/fsoa-2020-0209] [Reference Citation Analysis]
77 von Bredow L, Schäfer TM, Hogenkamp J, Tretbar M, Stopper D, Kraft FB, Schliehe-diecks J, Schöler A, Borkhardt A, Bhatia S, Held J, Hansen FK. Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs. Pharmaceuticals 2022;15:333. [DOI: 10.3390/ph15030333] [Reference Citation Analysis]
78 He F, Chou CJ, Scheiner M, Poeta E, Yuan Chen N, Gunesch S, Hoffmann M, Sotriffer C, Monti B, Maurice T, Decker M. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model. J Med Chem 2021;64:3794-812. [PMID: 33769811 DOI: 10.1021/acs.jmedchem.0c01940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
79 Jiang X, Wang Y, Liu C, Xing C, Wang Y, Lyu W, Wang S, Li Q, Chen T, Chen Y, Feng F, Liu W, Sun H. Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. Bioorganic & Medicinal Chemistry 2021;30:115940. [DOI: 10.1016/j.bmc.2020.115940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
80 Li X, Li X, Liu F, Li S, Shi D. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. J Med Chem 2021;64:10581-605. [PMID: 34313432 DOI: 10.1021/acs.jmedchem.1c00683] [Reference Citation Analysis]
81 Jensen KB, Mikkelsen JH, Jensen SP, Kidal S, Friberg G, Skrydstrup T, Gustafsson MBF. New Phenol Esters for Efficient pH-Controlled Amine Acylation of Peptides, Proteins, and Sepharose Beads in Aqueous Media. Bioconjug Chem 2021. [PMID: 34962390 DOI: 10.1021/acs.bioconjchem.1c00528] [Reference Citation Analysis]
82 Dong Y, Zhang X, Liu M, Yang Y, Guo T, Mao Y, Zhang J, Fu X, Zhao Y, Chen J, Dong L, Qiao C. Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke. Bioorg Med Chem Lett 2019;29:126608. [PMID: 31444086 DOI: 10.1016/j.bmcl.2019.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Lago-Fernandez A, Zarzo-Arias S, Jagerovic N, Morales P. Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. Int J Mol Sci 2021;22:1001. [PMID: 33498245 DOI: 10.3390/ijms22031001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Gorecki L, Misiachna A, Damborsky J, Dolezal R, Korabecny J, Cejkova L, Hakenova K, Chvojkova M, Karasova JZ, Prchal L, Novak M, Kolcheva M, Kortus S, Vales K, Horak M, Soukup O. Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors. Eur J Med Chem 2021;219:113434. [PMID: 33892271 DOI: 10.1016/j.ejmech.2021.113434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Gonzalez S, Dumitrascuta M, Eiselt E, Louis S, Kunze L, Blasiol A, Vivancos M, Previti S, Dewolf E, Martin C, Tourwé D, Cavelier F, Gendron L, Sarret P, Spetea M, Ballet S. Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. J Med Chem 2020;63:12929-41. [PMID: 32902268 DOI: 10.1021/acs.jmedchem.0c01376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Prasher P, Sharma M, Aljabali AAA, Gupta G, Negi P, Kapoor DN, Singh I, Zacconi FC, Jesus Andreoli Pinto T, Silva MW, Bakshi HA, Chellappan DK, Tambuwala MM, Dua K. Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review. Drug Dev Res 2020;81:837-58. [DOI: 10.1002/ddr.21704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
87 Łażewska D, Zaręba P, Godyń J, Doroz-Płonka A, Frank A, Reiner-Link D, Bajda M, Stary D, Mogilski S, Olejarz-Maciej A, Kaleta M, Stark H, Malawska B, Kieć-Kononowicz K. Biphenylalkoxyamine Derivatives-Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity. Molecules 2021;26:3580. [PMID: 34208297 DOI: 10.3390/molecules26123580] [Reference Citation Analysis]
88 Huentupil Y, Chung P, Novoa N, Arancibia R, Roussel P, Oyarzo J, Klahn AH, Silva C, Calvis C, Messeguer R, Bosque R, López C. Novel multifunctional and multitarget homo- (Fe2) and heterobimetallic [(Fe,M) with M = Re or Mn] sulfonyl hydrazones. Dalton Trans 2020;49:12249-65. [PMID: 32832967 DOI: 10.1039/d0dt01756f] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Andring JT, Dohle W, Tu C, Potter BVL, McKenna R. 3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity. J Med Chem 2019;62:2202-12. [PMID: 30721041 DOI: 10.1021/acs.jmedchem.8b01990] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
90 Elzahhar PA, Abd El Wahab SM, Elagawany M, Daabees H, Belal AS, El-yazbi AF, Eid AH, Alaaeddine R, Hegazy RR, Allam RM, Helmy MW, Bahaa Elgendy, Angeli A, El-hawash SA, Supuran CT. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases. European Journal of Medicinal Chemistry 2020;200:112439. [DOI: 10.1016/j.ejmech.2020.112439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
91 Alachkar A, Khan N, Łażewska D, Kieć-Kononowicz K, Sadek B. Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats. Neuropsychiatr Dis Treat 2019;15:531-42. [PMID: 30863075 DOI: 10.2147/NDT.S193125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
92 Li S, Wang F, Zhang G, Chou T. NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells. Pharmaceutics 2022;14:764. [DOI: 10.3390/pharmaceutics14040764] [Reference Citation Analysis]
93 Albertini C, Salerno A, Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. Med Res Rev 2021;41:2606-33. [DOI: 10.1002/med.21699] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
94 Procházková E, Kucherak O, Stodůlková E, Tošner Z, Císařová I, Flieger M, Kolařík M, Baszczyňski O. NMR Structure Elucidation of Naphthoquinones from Quambalaria cyanescens. J Nat Prod 2021;84:46-55. [PMID: 33342211 DOI: 10.1021/acs.jnatprod.0c00930] [Reference Citation Analysis]
95 Feldmann C, Bajorath J. Compounds with multitarget activity: structure-based analysis and machine learning. Future Drug Discovery 2020;2:FDD44. [DOI: 10.4155/fdd-2020-0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
96 Yumura M, Nagano T, Nishimura Y. Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. Molecules 2020;25:E3987. [PMID: 32882995 DOI: 10.3390/molecules25173987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
97 Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 2020;10:2585. [PMID: 32066817 DOI: 10.1038/s41598-020-59074-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
98 Marques MPM, Batista de Carvalho ALM, Mamede AP, Rudić S, Dopplapudi A, García Sakai V, Batista de Carvalho LAE. Intracellular water as a mediator of anticancer drug action. International Reviews in Physical Chemistry 2020;39:67-81. [DOI: 10.1080/0144235x.2020.1700083] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
99 Brandão P, López Ó, Leitzbach L, Stark H, Fernández-Bolaños JG, Burke AJ, Pineiro M. Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors. ACS Med Chem Lett 2021;12:1718-25. [PMID: 34795859 DOI: 10.1021/acsmedchemlett.1c00344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
100 Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel) 2021;13:634. [PMID: 33562653 DOI: 10.3390/cancers13040634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
101 Codony S, Pont C, Griñán-Ferré C, Di Pede-Mattatelli A, Calvó-Tusell C, Feixas F, Osuna S, Jarné-Ferrer J, Naldi M, Bartolini M, Loza MI, Brea J, Pérez B, Bartra C, Sanfeliu C, Juárez-Jiménez J, Morisseau C, Hammock BD, Pallàs M, Vázquez S, Muñoz-Torrero D. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. J Med Chem 2022. [PMID: 35271276 DOI: 10.1021/acs.jmedchem.1c02150] [Reference Citation Analysis]
102 Thakur A, Tawa GJ, Henderson MJ, Danchik C, Liu S, Shah P, Wang AQ, Dunn G, Kabir M, Padilha EC, Xu X, Simeonov A, Kharbanda S, Stone R, Grewal G. Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J Med Chem 2020;63:4256-92. [PMID: 32212730 DOI: 10.1021/acs.jmedchem.0c00193] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
103 Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021;25:1315-60. [PMID: 33844136 DOI: 10.1007/s11030-021-10217-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
104 Alves VM, Korn D, Pervitsky V, Thieme A, Capuzzi SJ, Baker N, Chirkova R, Ekins S, Muratov EN, Hickey A, Tropsha A. Knowledge-based approaches to drug discovery for rare diseases. Drug Discov Today 2021:S1359-6446(21)00452-9. [PMID: 34718207 DOI: 10.1016/j.drudis.2021.10.014] [Reference Citation Analysis]
105 Pinzi L. On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Res 2022;11:237. [DOI: 10.12688/f1000research.108761.1] [Reference Citation Analysis]
106 Sampietro A, Pérez-areales FJ, Martínez P, Arce EM, Galdeano C, Muñoz-torrero D. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals 2022;15:545. [DOI: 10.3390/ph15050545] [Reference Citation Analysis]
107 Feldmann C, Bajorath J. Differentiating Inhibitors of Closely Related Protein Kinases with Single- or Multi-Target Activity via Explainable Machine Learning and Feature Analysis. Biomolecules 2022;12:557. [DOI: 10.3390/biom12040557] [Reference Citation Analysis]
108 Huo X, Gu Y, Zhang Y. The discovery of multi-target compounds with anti-inflammation activity from traditional Chinese medicine by TCM-target effects relationship spectrum. J Ethnopharmacol 2022;:115289. [PMID: 35427724 DOI: 10.1016/j.jep.2022.115289] [Reference Citation Analysis]
109 Feldmann C, Philipps M, Bajorath J. Explainable machine learning predictions of dual-target compounds reveal characteristic structural features. Sci Rep 2021;11:21594. [PMID: 34732806 DOI: 10.1038/s41598-021-01099-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Falkenstein M, Reiner-Link D, Zivkovic A, Gering I, Willbold D, Stark H. Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation. Bioorg Med Chem 2021;50:116462. [PMID: 34695709 DOI: 10.1016/j.bmc.2021.116462] [Reference Citation Analysis]
111 Pérez-Areales FJ, Turcu AL, Barniol-Xicota M, Pont C, Pivetta D, Espargaró A, Bartolini M, De Simone A, Andrisano V, Pérez B, Sabate R, Sureda FX, Vázquez S, Muñoz-Torrero D. A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. Eur J Med Chem 2019;180:613-26. [PMID: 31351393 DOI: 10.1016/j.ejmech.2019.07.051] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
112 Schierle S, Brunst S, Helmstädter M, Ebert R, Kramer JS, Steinhilber D, Proschak E, Merk D. Development and in vitro Profiling of Dual FXR/LTA4H Modulators. ChemMedChem 2021;16:2366-74. [PMID: 33856122 DOI: 10.1002/cmdc.202100118] [Reference Citation Analysis]
113 Yan Z, Zhang K, Ji M, Xu H, Chen X. A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. Front Pharmacol 2021;12:741697. [PMID: 34658878 DOI: 10.3389/fphar.2021.741697] [Reference Citation Analysis]
114 Warda ET, Shehata IA, El-ashmawy MB, El-gohary NS. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Bioorganic & Medicinal Chemistry 2020;28:115674. [DOI: 10.1016/j.bmc.2020.115674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
115 Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today 2022;27:8-16. [PMID: 34600126 DOI: 10.1016/j.drudis.2021.09.016] [Reference Citation Analysis]
116 Cinar R, Iyer MR, Kunos G. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19. Br J Pharmacol 2021. [PMID: 33769552 DOI: 10.1111/bph.15461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
117 Humbeck L, Pretzel J, Spitzer S, Koch O. Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ. ACS Chem Biol 2021;16:1255-65. [PMID: 34180651 DOI: 10.1021/acschembio.1c00323] [Reference Citation Analysis]
118 Sobolova K, Hrabinova M, Hepnarova V, Kucera T, Kobrlova T, Benkova M, Janockova J, Dolezal R, Prchal L, Benek O, Mezeiova E, Jun D, Soukup O, Korabecny J. Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile. Eur J Med Chem 2020;203:112593. [PMID: 32688201 DOI: 10.1016/j.ejmech.2020.112593] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
119 Stelitano G, Sammartino JC, Chiarelli LR. Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis. Molecules 2020;25:E1239. [PMID: 32182964 DOI: 10.3390/molecules25051239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Mathai N, Chen Y, Kirchmair J. Validation strategies for target prediction methods. Brief Bioinform 2020;21:791-802. [PMID: 31220208 DOI: 10.1093/bib/bbz026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
121 Pinzi L, Rastelli G. Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. J Chem Inf Model 2020;60:372-90. [PMID: 31800237 DOI: 10.1021/acs.jcim.9b00821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Svobodova B, Mezeiova E, Hepnarova V, Hrabinova M, Muckova L, Kobrlova T, Jun D, Soukup O, Jimeno ML, Marco-Contelles J, Korabecny J. Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors. Biomolecules 2019;9:E379. [PMID: 31430943 DOI: 10.3390/biom9080379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
123 Ammazzalorso A, Maccallini C, Amoia P, Amoroso R. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. European Journal of Medicinal Chemistry 2019;173:261-73. [DOI: 10.1016/j.ejmech.2019.04.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
124 Grillo A, Chemi G, Brogi S, Brindisi M, Relitti N, Fezza F, Fazio D, Castelletti L, Perdona E, Wong A, Lamponi S, Pecorelli A, Benedusi M, Fantacci M, Valoti M, Valacchi G, Micheli F, Novellino E, Campiani G, Butini S, Maccarrone M, Gemma S. Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. European Journal of Medicinal Chemistry 2019;183:111674. [DOI: 10.1016/j.ejmech.2019.111674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
125 Szczepańska K, Podlewska S, Dichiara M, Gentile D, Patamia V, Rosier N, Mönnich D, Ruiz Cantero MC, Karcz T, Łażewska D, Siwek A, Pockes S, Cobos EJ, Marrazzo A, Stark H, Rescifina A, Bojarski AJ, Amata E, Kieć-Kononowicz K. Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties. ACS Chem Neurosci 2022;13:1-15. [PMID: 34908391 DOI: 10.1021/acschemneuro.1c00435] [Reference Citation Analysis]
126 Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin Ther Pat 2020;30:263-74. [PMID: 32008402 DOI: 10.1080/13543776.2020.1725470] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
127 Miljković F, Bajorath J. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome. J Comput Aided Mol Des 2020;34:1-10. [DOI: 10.1007/s10822-019-00266-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
128 de Lera AR, Ganesan A. Two-hit wonders: The expanding universe of multitargeting epigenetic agents. Current Opinion in Chemical Biology 2020;57:135-54. [DOI: 10.1016/j.cbpa.2020.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
129 Zięba A, Stępnicki P, Matosiuk D, Kaczor AA. What are the challenges with multi-targeted drug design for complex diseases? Expert Opin Drug Discov 2022;:1-11. [PMID: 35549603 DOI: 10.1080/17460441.2022.2072827] [Reference Citation Analysis]
130 Olomola TO, Mphahlele MJ, Gildenhuys S. Benzofuran-selenadiazole hybrids as novel α-glucosidase and cyclooxygenase-2 inhibitors with antioxidant and cytotoxic properties. Bioorg Chem 2020;100:103945. [PMID: 32450390 DOI: 10.1016/j.bioorg.2020.103945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
131 Lutsenko K, Hagenow S, Affini A, Reiner D, Stark H. Rasagiline derivatives combined with histamine H3 receptor properties. Bioorganic & Medicinal Chemistry Letters 2019;29:126612. [DOI: 10.1016/j.bmcl.2019.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
132 Wu S, Huang Y, Wang T, Li K, Lu J, Huang M, Dong G, Sheng C. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. J Med Chem 2022. [PMID: 35238576 DOI: 10.1021/acs.jmedchem.1c02026] [Reference Citation Analysis]
133 De Simone A, Tumiatti V, Andrisano V, Milelli A. Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery? J Med Chem 2021;64:26-41. [PMID: 33346659 DOI: 10.1021/acs.jmedchem.0c00931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
134 Chan AM, Fletcher S. Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Med Chem 2021;12:178-96. [PMID: 34046608 DOI: 10.1039/d0md00286k] [Reference Citation Analysis]
135 Hefke L, Hiesinger K, Zhu WF, Kramer JS, Proschak E. Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase. ACS Med Chem Lett 2020;11:1244-9. [PMID: 32551007 DOI: 10.1021/acsmedchemlett.0c00102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
136 Gilberg E, Bajorath J. Recent Progress in Structure-Based Evaluation of Compound Promiscuity. ACS Omega 2019;4:2758-65. [DOI: 10.1021/acsomega.8b03639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
137 Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Rezvani Jalal N, West R, Dastghaib S, Igder S, Torshizi SRN, Mahmoodzadeh A, Mokarram P, Madrakian T, Albensi BC, Łos MJ, Ghavami S, Pecic S. Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacol Ther 2022;237:108171. [PMID: 35304223 DOI: 10.1016/j.pharmthera.2022.108171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Dong Y, Hu H, Sun Y, Qin M, Gong P, Hou Y, Zhao Y. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. Bioorg Med Chem Lett 2020;30:127610. [PMID: 33045329 DOI: 10.1016/j.bmcl.2020.127610] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Chandrasekaran SN, Ceulemans H, Boyd JD, Carpenter AE. Image-based profiling for drug discovery: due for a machine-learning upgrade? Nat Rev Drug Discov 2021;20:145-59. [PMID: 33353986 DOI: 10.1038/s41573-020-00117-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
140 Galieni A, Falcinelli B, Stagnari F, Datti A, Benincasa P. Sprouts and Microgreens: Trends, Opportunities, and Horizons for Novel Research. Agronomy 2020;10:1424. [DOI: 10.3390/agronomy10091424] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 15.5] [Reference Citation Analysis]
141 Brunetti L, Loiodice F, Piemontese L, Tortorella P, Laghezza A. New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation. J Med Chem 2019;62:10995-1003. [PMID: 31407888 DOI: 10.1021/acs.jmedchem.9b00885] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
142 Meziant L, Bachir-bey M, Bensouici C, Saci F, Boutiche M, Louaileche H. Assessment of inhibitory properties of flavonoid-rich fig (Ficus carica L.) peel extracts against tyrosinase, α-glucosidase, urease and cholinesterases enzymes, and relationship with antioxidant activity. European Journal of Integrative Medicine 2021;43:101272. [DOI: 10.1016/j.eujim.2020.101272] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Mok SW, Wong VK, Lo H, de Seabra Rodrigues Dias IR, Leung EL, Law BY, Liu L. Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders. Pharmacology & Therapeutics 2020;208:107480. [DOI: 10.1016/j.pharmthera.2020.107480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
144 Ge J, Yin Y, Li Y, Deng Y, Fu H. Dual-target inhibitors based on PARP1: new trend in the development of anticancer research. Future Med Chem 2022. [PMID: 35257598 DOI: 10.4155/fmc-2021-0292] [Reference Citation Analysis]
145 Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J. Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation. RSC Adv 2019;9:37092-100. [DOI: 10.1039/c9ra08954c] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Mensa-Wilmot K. How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins. Mol Pharmacol 2021;100:1-6. [PMID: 33941662 DOI: 10.1124/molpharm.120.000186] [Reference Citation Analysis]
147 Park H, Jung HY, Mah S, Kim K, Hong S. Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines. Org Biomol Chem 2020;18:8402-13. [PMID: 33112339 DOI: 10.1039/d0ob01917h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Zhong Y, Qiu RZ, Sun SL, Zhao C, Fan TY, Chen M, Li NG, Shi ZH. Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. J Med Chem 2020;63:12403-28. [PMID: 32659083 DOI: 10.1021/acs.jmedchem.0c00696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
149 Stumpfe D, Hoch A, Bajorath J. Introducing the metacore concept for multi-target ligand design. RSC Med Chem 2021;12:628-35. [PMID: 34046634 DOI: 10.1039/d1md00056j] [Reference Citation Analysis]
150 Kampen S, Duy Vo D, Zhang X, Panel N, Yang Y, Jaiteh M, Matricon P, Svenningsson P, Brea J, Loza MI, Kihlberg J, Carlsson J. Structure-Guided Design of G-Protein-Coupled Receptor Polypharmacology. Angew Chem Int Ed Engl 2021;60:18022-30. [PMID: 33904641 DOI: 10.1002/anie.202101478] [Reference Citation Analysis]
151 Helmstädter M, Schmidt J, Kaiser A, Weizel L, Proschak E, Merk D. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacol Transl Sci 2021;4:966-79. [PMID: 33860214 DOI: 10.1021/acsptsci.1c00041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Shaheen MA, El-emam AA, El-gohary NS. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Bioorganic Chemistry 2020;105:104274. [DOI: 10.1016/j.bioorg.2020.104274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Kobayashi T, Hosoya T, Yoshida S. Consecutive Aryne Generation Strategy for the Synthesis of 1,3-Diarylpyrazoles. J Org Chem 2020;85:4448-62. [DOI: 10.1021/acs.joc.0c00172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
154 Mashelkar KK, Byun WS, Ko H, Sung K, Tripathi SK, An S, Yum YA, Kwon JY, Kim M, Kim G, Kwon EJ, Lee HW, Noh M, Lee SK, Jeong LS. Discovery of a Novel Template, 7-Substituted 7-Deaza-4'-Thioadenosine Derivatives as Multi-Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:1290. [PMID: 34959689 DOI: 10.3390/ph14121290] [Reference Citation Analysis]
155 Bajan S, Hutvagner G. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells 2020;9:E137. [PMID: 31936122 DOI: 10.3390/cells9010137] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 39.5] [Reference Citation Analysis]
156 Hiesinger K, Schott A, Kramer JS, Blöcher R, Witt F, Wittmann SK, Steinhilber D, Pogoryelov D, Gerstmeier J, Werz O, Proschak E. Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase. ACS Med Chem Lett 2020;11:298-302. [PMID: 32184960 DOI: 10.1021/acsmedchemlett.9b00330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
157 Ma H, Huang B, Zhang Y. Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. Drug Discov Today 2020;25:1682-92. [PMID: 32652312 DOI: 10.1016/j.drudis.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
158 Feldmann C, Yonchev D, Stumpfe D, Bajorath J. Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. Mol Pharm 2020;17:4652-66. [PMID: 33151084 DOI: 10.1021/acs.molpharmaceut.0c00901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
159 Newman DJ. Modern traditional Chinese medicine: Identifying, defining and usage of TCM components. Pharmacological Advances in Natural Product Drug Discovery. Elsevier; 2020. pp. 113-58. [DOI: 10.1016/bs.apha.2019.07.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
160 Feldmann C, Bajorath J. Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. Sci Rep 2021;11:7863. [PMID: 33846469 DOI: 10.1038/s41598-021-87042-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
161 Helmstädter M, Kaiser A, Brunst S, Schmidt J, Ronchetti R, Weizel L, Proschak E, Merk D. Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. J Med Chem 2021;64:9525-36. [PMID: 34165993 DOI: 10.1021/acs.jmedchem.1c00831] [Reference Citation Analysis]
162 Zhang K, Lai F, Lin S, Ji M, Zhang J, Zhang Y, Jin J, Fu R, Wu D, Tian H, Xue N, Sheng L, Zou X, Li Y, Chen X, Xu H. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. J Med Chem 2019;62:6992-7014. [DOI: 10.1021/acs.jmedchem.9b00390] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
163 Borgonetti V, Meacci E, Pierucci F, Romanelli MN, Galeotti N. Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury. Neurotherapeutics 2022. [PMID: 35501470 DOI: 10.1007/s13311-022-01243-6] [Reference Citation Analysis]
164 Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug Des Devel Ther 2020;14:3235-49. [PMID: 32884235 DOI: 10.2147/DDDT.S257494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
165 Skok Ž, Zidar N, Kikelj D, Ilaš J. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. J Med Chem 2020;63:884-904. [DOI: 10.1021/acs.jmedchem.9b00726] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
166 Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, Arimondo PB, Glaser P, Aigle B, Bode HB, Moreira R, Li Y, Luzhetskyy A, Medema MH, Pernodet JL, Stadler M, Tormo JR, Genilloud O, Truman AW, Weissman KJ, Takano E, Sabatini S, Stegmann E, Brötz-Oesterhelt H, Wohlleben W, Seemann M, Empting M, Hirsch AKH, Loretz B, Lehr CM, Titz A, Herrmann J, Jaeger T, Alt S, Hesterkamp T, Winterhalter M, Schiefer A, Pfarr K, Hoerauf A, Graz H, Graz M, Lindvall M, Ramurthy S, Karlén A, van Dongen M, Petkovic H, Keller A, Peyrane F, Donadio S, Fraisse L, Piddock LJV, Gilbert IH, Moser HE, Müller R. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem 2021;:1-24. [PMID: 34426795 DOI: 10.1038/s41570-021-00313-1] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
167 Feldmann C, Bajorath J. X-ray Structure-Based Chemoinformatic Analysis Identifies Promiscuous Ligands Binding to Proteins from Different Classes with Varying Shapes. Int J Mol Sci 2020;21:E3782. [PMID: 32471121 DOI: 10.3390/ijms21113782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
168 Di Martino RMC, Cavalli A, Bottegoni G. Dopamine D3 receptor ligands: a patent review (2014-2020). Expert Opin Ther Pat 2022. [PMID: 35235753 DOI: 10.1080/13543776.2022.2049240] [Reference Citation Analysis]
169 Martínez R, Geronimo BD, Pastor M, Zapico JM, Coderch C, Panchuk R, Skorokhyd N, Maslyk M, Ramos A, de Pascual-Teresa B. Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors. Molecules 2020;25:E1497. [PMID: 32218358 DOI: 10.3390/molecules25071497] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
170 Kim M, Pandit S, Jee J. Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments. Pharmaceuticals 2022;15:236. [DOI: 10.3390/ph15020236] [Reference Citation Analysis]
171 Benek O, Korabecny J, Soukup O. A Perspective on Multi-target Drugs for Alzheimer's Disease. Trends Pharmacol Sci 2020;41:434-45. [PMID: 32448557 DOI: 10.1016/j.tips.2020.04.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 22.5] [Reference Citation Analysis]
172 Stark H. The chemical probe - scopes, limitations and challenges. Expert Opin Drug Discov 2020;15:1365-7. [PMID: 32551991 DOI: 10.1080/17460441.2020.1781086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]